September 10, 2025Cancer ReportsOpen Access

Co‐Expression of MHC‐II and ANXA1: Mediators of PD‐1/PD‐L1 Therapy Resistance in Breast Cancer

View Full Paper

Ask AI

Bookmark

MHC-II expression influences immune evasion and treatment responses in triple-negative breast cancer.
Differential expression analysis revealed significant changes in gene profiles associated with MHC-II and immunotherapy.
Mendelian randomization identified links between specific genes and PD-L1 status in breast cancer patients.
ANXA1 expression decreases in breast cancer and correlates with immunotherapy resistance, indicating its value as a therapeutic target.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Observational analysis highlights MHC-II and ANXA1 involvement in therapy resistance in triple-negative breast cancer, suggesting new biomarkers for treatment strategy.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/68c23f63b210217d64797136 https://doi.org/10.1002/cnr2.70291

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis highlights MHC-II and ANXA1 involvement in therapy resistance in triple-negative breast cancer, suggesting new biomarkers for treatment strategy.

Co‐Expression of MHC‐II and ANXA1: Mediators of PD‐1/PD‐L1 Therapy Resistance in Breast Cancer

Key Points

Discussion

Implication

Cite This Study

Co‐Expression of MHC‐II and ANXA1: Mediators of PD‐1/PD‐L1 Therapy Resistance in Breast Cancer

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading